Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

Using Sotrovimab to treat COVID-19 early

A new study published on the medRxiv* preprint server hypothesized that a monoclonal antibody that has the capability to neutralize all sarbecoviruses could also be used to target a highly conserved epitope. This conserved sequence has a high probability of remaining unchanged in SARS-CoV-2 variants.

31 May 2021

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

A new study has been published in the Journal of Biomolecular Structure and Dynamics which focuses on the evaluation of E, M, N, ORF10, ORF8, ORF3a, and M proteins using bioinformatics tools to develop a multi-epitope COVID-19 vaccine. The researchers utilized in-silico methods to incite humoral and cellular immune responses.

31 May 2021

Vagus nerve stimulation may be a potential adjunct therapy for COVID-19

COVID-19 was initially described as lung inflammation, or pneumonia, in older adults. However, we now know that SARS-CoV-2 infections can cause a wide range of symptoms in people of all ages, ranging from no symptoms at all to systemic inflammation and even death.

27 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

How do common mutations in SARS-CoV-2’s spike affect its binding affinity with host cell receptors?

Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.

21 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.

19 May 2021

Researchers examine potential SARS-CoV-2 antivirals using a drug repurposing library

A new study deals with the screening of the Drug Repurposing Hub (DRH) library for identifying small compounds which are capable of inhibiting SARS-CoV-2 using both in vitro and in vivo experimental studies. These molecules could be used for designing a novel therapeutic system against SARS-CoV-2 infection.

26 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021